BCRX — BioCryst Pharmaceuticals, Inc. stock price, charts and financials

QT67BioCryst Pharmaceuticals, Inc.

BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
9.60
+0.22+2.38%
OverviewShort InterestFilings
BCRXQT67BioCryst Pharmaceuticals, Inc.·NASDAQ
9.60+2.38%
TA
Loading chart...
Signal & projected range
Earnings big beat — drift (PEAD)Historical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Premium shows the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands ofhistorical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
IMNM+3.20%$25.83VERA-3.15%$31.85MLYS-0.29%$27.27KLRA-0.64%$18.54PHVS+0.52%$35.09VCEL-1.03%$44.63SION-92.03%$4.07ZLAB+0.49%$23.43
Snapshot
Index-P/E-EPS (ttm)-1.78Insider Own2.64%Shs Outstand254.16MPerf Week4.45%
Market Cap2.38BForward P/E17.08EPS next Y0.55Insider Trans-4.08%Shs Float214.93MPerf Month-12.50%
Enterprise Value2.64BPEG0.00EPS next Q-Inst Own-Short Float14.52%Perf Quarter5.39%
Income-384.31MP/S2.53EPS this Y-29.30%Inst Trans-Short Ratio6.16Perf Half Y50.32%
Sales940.63MP/B-EPS next Y123.87%ROA-68.96%Short Interest31.21MPerf YTD20.26%
Book/sh-P/C6.63EPS next 5Y-ROE101.55%52W High11.49 -16.40%Perf Year9.07%
Cash/sh-P/FCF6.66EPS past 3/5Y-ROIC-88.96%52W Low6.14 56.33%Perf 3Y34.96%
Dividend Est.-EV/EBITDA-Sales past 3/5Y47.80% 117.44%Gross Margin23.52%Volatility5.35% 4.09%Perf 5Y-41.81%
Dividend TTM-EV/Sales2.81EPS Y/Y TTM-313.95%Oper. Margin-33.29%ATR (14)0.44Perf 10Y171.10%
Dividend Ex-Date-Quick Ratio2.29Sales Y/Y TTM96.23%Profit Margin-40.90%RSI (14)50.01Recom2.14
Dividend Gr. 3/5Y-Current Ratio2.32EPS Q/Q-SMA200.39%Beta0.57Target Price20.00
Payout0.00%Debt/Eq-Sales Q/Q6.85%SMA500.70%Rel Volume0.90Prev Close9.38
Employees435LT Debt/Eq-3.67EarningsNov 02SMA20013.10%Avg Volume4.85MPrice9.60
IPO DateMar 04, 1994Option/ShortYes / YesEPS/Sales Surpr.-6831.88% 3.50%Net Debt/EBITDA-0.84Volume4,382,818Change2.38%
Analyst Ratings
DateActionAnalystRatingTarget
Jul-07-26ReiteratedRBC CapitalOutperform$15 → $14
Jun-30-26ReiteratedJefferiesBuy$15 → $17
Jun-30-26ReiteratedCantor FitzgeraldOverweight$21 → $29
Nov-05-25ReiteratedJMP SecuritiesMarket Outperform$27 → $25
Nov-04-25ReiteratedBarclaysEqual Weight$7.00 → $9.00
Oct-14-25ReiteratedRBC CapitalOutperform$15
Oct-14-25ReiteratedJefferiesBuy$14 → $15
Oct-01-25ReiteratedEvercore ISIOutperform$16 → $8.00
Aug-06-24ReiteratedBarclaysEqual Weight$14 → $7.00
Aug-05-24ReiteratedJefferiesBuy$19 → $11
Latest News
Aug-05-26
Aug-05-2612:28PM
BioCryst Pharmaceuticals (NASDAQ:BCRX) Surges on Q2 Earnings BeatChartMill
12:00PM
BioCryst Pharmaceuticals, Inc. (BCRX) Q2 2026 Earnings Call Transcriptseekingalpha.com
10:07AM
BioCryst Pharmaceuticals Q2 Earnings Call Highlightsmarketbeat.com
10:01AM
BioCryst Pharmaceuticals (BCRX) Tops Q2 Earnings and Revenue Estimateszacks.com
07:00AM
BioCryst Reports Second Quarter 2026 Financial Resultsglobenewswire.com
Jul-30-26
Jul-30-2603:37AM
ADAR1 Capital Management LLC Has $1 Million Stock Holdings in BioCryst Pharmaceuticals, Inc. $BCRXdefenseworld.net
Jul-22-26
Jul-22-2607:00AM
BioCryst to Report Second Quarter 2026 Financial Results on August 5globenewswire.com
Jul-15-26
Jul-15-2607:00AM
BioCryst Appoints David W. Jenkins as Chief Scientific Officerglobenewswire.com
Jul-14-26
Jul-14-2610:56AM
Wall Street Analysts Think BioCryst (BCRX) Could Surge 117.96%: Read This Before Placing a Betzacks.com
Jul-13-26
Jul-13-2607:06AM
JP Morgan Reinstates Neutral on BioCryst Pharma, Announces $12 Price TargetBenzinga
Jul-08-26
Jul-08-2611:16AM
BioCryst (BCRX) Surges 8.1%: Is This an Indication of Further Gains?zacks.com
Jul-07-26
Jul-07-2611:35AM
RBC Capital Maintains Outperform on BioCryst Pharma, Raises Price Target to $14Benzinga
Jul-02-26
Jul-02-2607:00AM
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)globenewswire.com
Jun-29-26
Jun-29-2608:21AM
BioCryst scraps internal drug discovery programs, leans on partnerships to cut costsreuters.com
07:00AM
BioCryst Sharpens Scientific Focus on External Innovation with Wind Down of Internal Discovery Programs and Closure of Birmingham Research Facilityglobenewswire.com
Company

BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on discovering and developing novel, orally administered, small-molecule therapeutics. The company currently markets two key products: Peramivir injection: An intravenous neuraminidase inhibitor, sold under the brand names RAPIVAB, RAPIACTA, and PERAMIFLU, used for the treatment of acute uncomplicated influenza. ORLADEYO: An oral serine protease inhibitor designed to manage hereditary angioedema. BioCryst's development pipeline includes several promising candidates: BCX9930: An oral factor D inhibitor in Phase II clinical trials for complement-mediated diseases. BCX9250: An oral activin receptor-like kinase-2 inhibitor undergoing Phase I clinical evaluation for fibrodysplasia ossificans progressiva. Galidesivir: An RNA dependent-RNA polymerase inhibitor, also in Phase I, aimed at treating a range of RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company engages in strategic collaborations and in-license agreements with numerous partners. These include pharmaceutical entities like Torii Pharmaceutical Co., Ltd., Seqirus UK Limited, Shionogi & Co., Ltd., Green Cross Corporation, and Mundipharma International Holdings Limited. Their alliances also extend to governmental and academic organizations such as the National Institute of Allergy and Infectious Diseases, the Biomedical Advanced Research and Development Authority, the U.S. Department of Health and Human Services, The University of Alabama at Birmingham, Albert Einstein College of Medicine of Yeshiva University, and Industrial Research, Ltd. Established in 1986, BioCryst Pharmaceuticals, Inc. is headquartered in Durham, North Carolina.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue940875451——————
Cost of Goods Sold Incl. D&A7201912——————
Gross Profit221856438——————
Selling, General and Administrative Excl. Other338349266——————
Research and Development197166175——————
Other Operating Expense
000——————
Operating Income-314341-3——————
Interest Expense767999——————
Unusual Expense
—————————
Non-Operating Income (Expense)8514——————
Net Income Before Taxes-382267-87——————
Income Taxes342——————
Consolidated Net Income-385264-89——————
Net Income From Continuing Operations-385264-89——————
Net Income-385264-89——————
EPS (Recurring)-1.441.26-0.43——————
EPS (Basic, Before Extraordinaries)-1.441.26-0.43——————
EPS (Diluted)-1.501.21-0.43——————
EBITDA-30334813——————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio—6.45———————
Price To Sales Ratio2.591.873.45——————
Gross Margin23.5197.8397.12——————
Operating Margin-33.4038.97-0.67——————
Net Margin-40.9630.17-19.73——————
Shares Outstanding254210207——————
Market Capitalization2,4391,6381,557——————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
$11.93$10.32$8.71$7.11$5.50● Close Price0.00M0.47M0.94M1.41M1.88MUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
McKee Amy EDirectorMay 18 '26Sale8.9711,180100,28531,252May 19
Barnes Alane PChief Legal OfficerMay 13 '26Option Exercise5.0462,500315,000463,203May 15
Barnes Alane PChief Legal OfficerMay 13 '26Sale9.5462,500596,250400,703May 15
HEGGIE THERESADirectorMar 20 '26Option Exercise6.3049,933314,578115,285Mar 24
HEGGIE THERESADirectorMar 20 '26Sale10.1149,933504,82365,352Mar 24
Barnes Alane PChief Legal OfficerMar 16 '26Option Exercise5.51150,000826,500550,703Mar 18
Barnes Alane PChief Legal OfficerMar 16 '26Sale9.15150,0001,372,500400,703Mar 18
Stonehouse Jon PDirectorMar 02 '26Option Exercise3.22305,995985,3041,629,845Mar 03
Barnes Alane PChief Legal OfficerDec 22 '25Sale7.6521,773166,563398,751Dec 23
Gayer Charles KPresident and CCODec 22 '25Option Exercise5.0174,233371,896952,583Dec 23
Barnes Alane PChief Legal OfficerDec 15 '25Sale7.6521,210162,257315,726Dec 16
Barnes Alane PChief Legal OfficerDec 03 '25Sale7.6519,770151,241345,476Dec 03
Barnes Alane PChief Legal OfficerDec 02 '25Sale7.2150,906367,216365,246Dec 03
Barnes Alane PChief Legal OfficerDec 01 '25Sale7.1091,004646,511416,152Dec 03
Barnes Alane PChief Legal OfficerDec 01 '25Option Exercise3.2291,004293,033507,156Dec 03
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.